LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Eichelberg, Christian; Vervenne, Walter L.; De Santis, Maria; Fischer von Weikersthal, Ludwig; Goebell, Peter J.; Lerchenmüller, Christian; Zimmermann, Uwe; Bos, Monique M.E.M.; Freier, Werner; Schirrmacher-Memmel, Silke; Staehler, Michael; Pahernik, Sascha; Los, Maartje; Schenck, Marcus; Flörcken, Anne; van Arkel, Cornelis; Hauswald, Kirsten; Indorf, Martin; Gottstein, Dana; Michel, Maurice S. (2015)
Publisher: Elsevier BV
Journal: European Urology
Languages: English
Types: Article
Subjects: Urology, R1

Classified by OpenAIRE into

mesheuropmc: urologic and male genital diseases
Background\ud Understanding how to sequence targeted therapies for metastatic renal\ud cell carcinoma (mRCC) is important for maximisation of clinical benefit.\ud \ud Objectives\ud To prospectively evaluate sequential use of the multikinase inhibitors sorafenib followed by sunitinib (So-Su) versus sunitinib followed by sorafenib (Su-So) in patients with mRCC.\ud \ud Design, setting, and participants\ud The multicentre, randomised, open-label, phase 3 SWITCH study assessed So-Su versus Su-So in patients with mRCC without prior systemic therapy, and stratified by Memorial Sloan Kettering Cancer Center risk score (favourable or intermediate).\ud \ud Intervention\ud Patients were randomised to sorafenib 400 mg twice daily followed, on progression or intolerable toxicity, by sunitinib 50 mg once daily (4 wk on, 2 wk off) (So-Su), or vice versa (Su-So).\ud \ud Outcome measurements and statistical analysis\ud The primary endpoint was improvement in progression-free survival (PFS) with So-Su versus Su-So, assessed from randomisation to progression or death during second-line therapy. Secondary endpoints included overall survival (OS) and safety.\ud \ud Results and limitations\ud In total, 365 patients were randomised (So-Su, n = 182; Su-So, n = 183). There was no significant difference in total PFS between So-Su and Su-So (median 12.5 vs 14.9 mo; hazard ratio [HR] 1.01; 90% confidence interval [CI] 0.81–1.27; p = 0.5 for superiority). OS was similar for So-Su and Su-So (median 31.5 and 30.2 mo; HR 1.00, 90% CI 0.77–1.30; p = 0.5 for superiority). More So-Su patients than Su-So patients reached protocol-defined second-line therapy (57% vs 42%). Overall, adverse event rates were generally similar between the treatment arms. The most frequent any-grade treatment-emergent first-line adverse events were diarrhoea (54%) and hand-foot skin reaction (39%) for sorafenib; and diarrhoea (40%) and fatigue (40%) for sunitinib.\ud \ud Conclusions\ud Total PFS was not superior with So-Su versus Su-So. These results demonstrate that sorafenib followed by sunitinib and vice versa provide similar clinical benefit in mRCC.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Singer EA, Gupta GN, Marchalik D, Srinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 2013;25: 273-80.
    • [2] Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286-96.
    • [3] Porta C, Tortora G, Linassier C, et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol 2012;29:1896-907.
    • [4] Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 2012;38:981-7.
    • [5] Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
    • [6] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
    • [7] Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
    • [8] Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7.
    • [9] Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. European Association of Urology 2014.
    • [10] Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31: 3791-9.
    • [11] Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
    • [12] Buchler T, Pavlik T, Bortlicek Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol 2012;29:3321-4.
    • [13] Calvani N, Morelli F, Leo S, et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 2012;29:1908-13.
    • [14] Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54: 1373-8.
    • [15] Porta C, Procopio P, Cartenı` G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011;108: E250-7.
    • [16] Stenner F, Chastonay R, Liewen H, et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 2012;82:333-40.
    • [17] Porta C, Procopio G, Carteni G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. Presentation at the German Cancer Congress (DKK) 2010, abstr PO119.
    • [18] Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20: 289-96.
    • [19] Eichelberg C, Goebell PJ, Vervenne WL, et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Ann Oncol 2014;25(Suppl 4): 835P.
    • [20] Gschwend JE, Beeker A, De Santis M, et al. Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study). J Clin Oncol 2013;31(Suppl):TPS4591.
    • [21] Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14: 1287-94.
    • [22] Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24.
    • [23] Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
    • [24] Alimohamed N, Lee JL, Srinivas S, et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2014;12:e127-31.
    • [25] Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72.
    • [26] Filson CP, Redman BG, Dunn RL, Miller DC. Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology 2011;77:825-30.
    • [27] Porta C, Paglino C, Imarisio I, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 2011; 11:105.
    • [28] Ambring A, Bjorholt I, Lesen E, Stierner U, Oden A. Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish registerbased study. Med Oncol 2013;30:331-8.
    • [29] Escudier B, Porta C, Bono P, et al. Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014;32:1412-8.
    • [30] Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
    • [31] Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113.
    • [32] Hutson TE, Bellmunt J, Porta C, et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46:2432-40.
    • [33] Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013;108:311-8.
    • [34] Chu TF, Rupnick MA, Kerlela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-9.
    • [35] Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009;20:1535-42.
    • [36] Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013;1:72-8.
    • [37] Ivanyi P, Grunwald V. Confusion of therapeutic approaches. Dtsch Arztebl Int 2014;111:405.
    • [38] Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011;29:3450-6.
    • [39] Altena R, de Vries EG, Gietema JA, Perik PJ, van Veldhuisen DJ. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-9.
    • [40] Jensen SA, Hasbak P, Mortensen J, Sorensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010;28:5280-6.
    • [41] Haas NB, Manola J, Ky B, et al. Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). J Clin Oncol 2012; 30(Suppl):4500.
    • [42] Procopio G. Role of sorafenib in renal cell carcinoma: focus on elderly patients. Expert Rev Anticancer Ther 2011;11:1689-92.
    • [43] Procopio G, Derosa L, Gernone A, et al. Sorafenib as first- or secondline therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol 2014;10:1741-50.
    • [44] Derbel Miled O, Dionne C, Terret C, et al. Sorafenib and sunitinib for elderly patients with renal cell carcinoma. J Geriatr Oncol 2013;4: 255-61.
  • No similar publications.

Share - Bookmark

Cite this article